Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;188(9):2390-2406.e20.
doi: 10.1016/j.cell.2025.03.004. Epub 2025 Apr 8.

Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures

Affiliations

Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures

Huanhuan Li et al. Cell. .

Abstract

Skeletal muscle contraction is triggered by acetylcholine (ACh) binding to its ionotropic receptors (AChRs) at neuromuscular junctions. In myasthenia gravis (MG), autoantibodies target AChRs, disrupting neurotransmission and causing muscle weakness. While treatments exist, variable patient responses suggest pathogenic heterogeneity. Progress in understanding the molecular basis of MG has been limited by the absence of structures of intact human muscle AChRs. Here, we present high-resolution cryoelectron microscopy (cryo-EM) structures of the human adult AChR in different functional states. Using six MG patient-derived monoclonal antibodies, we mapped distinct epitopes involved in diverse pathogenic mechanisms, including receptor blockade, internalization, and complement activation. Electrophysiological and binding assays revealed how these autoantibodies directly inhibit AChR channel activation. These findings provide critical insights into MG immunopathogenesis, uncovering unrecognized antibody epitope diversity and modes of receptor inhibition, and provide a framework for developing personalized therapies targeting antibody-mediated autoimmune disorders.

Keywords: acetylcholine receptor; autoantibodies; autoimmune disease; cryoelectron microscopy; electrophysiology; ion channels; muscle weakness; myasthenia gravis; structural biology.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests K.C.O. is an equity shareholder of Cabaletta Bio, has received research support from Seismic Therapeutics and argenx, and serves on an advisory board for Seismic Therapeutics.

References

    1. Witzemann V (2006). Development of the neuromuscular junction. Cell and Tissue Research 326, 263–271. - PubMed
    1. Huijbers MG, Marx A, Plomp JJ, Le Panse R, and Phillips WD (2022). Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. The Lancet Neurology 21, 163–175. - PubMed
    1. Fichtner ML, Jiang R, Bourke A, Nowak RJ, and O’Connor KC (2020). Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology. Frontiers in Immunology 11. - PMC - PubMed
    1. Lazaridis K, and Tzartos SJ (2020). Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics. Frontiers in Immunology 11. - PMC - PubMed
    1. Howard JF Jr (2018). Myasthenia gravis: the role of complement at the neuromuscular junction. Annals of the New York Academy of Sciences 1412, 113–128. - PubMed

MeSH terms

LinkOut - more resources